In the month of March 2011, Camlin Fine Chemicals Ltd. acquired the Borreagaard Italy Plant. This is the
3rd largest plant in the manufacturing of Hydroquinone and Catechol.
Borregaard Italia manufactures Hydroquinone and Catechol at its plant in Ravenna, Italy. This plant has
the capacity to manufacture 3600 Mt of Hydroquinone and 4400 Mt of Catechol using proprietary
technology developed to ensure its customers with high quality products.
This plant set up in 1984 is fully automated from raw material charging to finished product packing. It is
located at a major industrial site together with other chemical plants. Part of the output is marketed as
intermediates for photo chemicals, rubber antioxidants and polymerisation inhibitors. Part of the output
is shipped to the diphenol derivatives plant located in Italy and India.
About Borregaard Synthesis
Borregaard Synthesis manufacturers fine chemicals for the global pharmaceutical market, with
streamlined core capabilities serving targeted applications including advanced intermediates, xray contrast media (XRCM) intermediates, active pharmaceutical ingredients (APIs), and
specialty excipients.
The business has engaged in a continual process of restructuring over the past decade,
consistent with streamlining to meet market needs. Borregaard Synthesis is focused on its core
capabilities and positioned to be highly competitive in meeting the demands of the modern
pharmaceutical market.
Corporate structure
Borregaard Synthesis is the fine chemicals division of the Borregaard Industries Limited, a
diversified business based in Norway with more than 115 years of history, and strong positions
in chemicals, ingredients, and energy. Alongside Borregaard Synthesis, Borregaard Lignotech
and Borregaard Chemcell divisions serve the specialty chemicals sector.
Borregaard is owned by Orkla – one of the largest listed companies in Norway in terms of
market capitalization. Orkla is diversified, with global strength in chemicals, branded consumer
goods, and financial investments.
The positioning of Borregaard Synthesis offers the advantages of being a smaller business within
a large corporate structure. The strength and diversity of Borregaard Industries and Orkla provide
stability, capital and logistic efficiencies for the fine chemicals business. However, operating as a
smaller independent entity enables Borregaard Synthesis to provide the flexibility and
responsiveness demanded and valued by modern pharmaceutical companies.